BECLOMETHASONE 17-MONOPROPIONATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H33ClO6
Molecular Weight	464.979
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BECLOMETHASONE 17-MONOPROPIONATE

Structure Search

SMILES

[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(Cl)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=OHYGPBKGZGRQKT-XGQKBEPLSA-N

InChI=1S/C25H33ClO6/c1-5-21(31)32-25(20(30)13-27)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,26)19(29)12-23(18,25)4/h8-9,11,14,17-19,27,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1

HIDE SMILES / InChI

Approval Year

C_max

Value	Dose	Co-administered	Analyte	Population
1.419 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12107606/	100 μg 4 times / day multiple, respiratory dose: 100 μg route of administration: Respiratory experiment type: MULTIPLE co-administered:		BECLOMETHASONE 17-MONOPROPIONATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4.985 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12107606/	100 μg 4 times / day multiple, respiratory dose: 100 μg route of administration: Respiratory experiment type: MULTIPLE co-administered:		BECLOMETHASONE 17-MONOPROPIONATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12107606/	100 μg 4 times / day multiple, respiratory dose: 100 μg route of administration: Respiratory experiment type: MULTIPLE co-administered:		BECLOMETHASONE 17-MONOPROPIONATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	Disc. AE: Epistaxis, Increased intraocular pressure... AEs leading to discontinuation/dose reduction: Epistaxis (5 patients) Increased intraocular pressure (1 patient) Colon cancer (2 patients) Nasal septum ulceration (2 patients) Nasal discomfort (2 patients) Sinusitis (2 patients) Nasal congestion (1 patient) Headache (1 patient) Nasal mucosal disorder (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	Disc. AE: Sinusitis, Nasopharyngitis... AEs leading to discontinuation/dose reduction: Sinusitis Nasopharyngitis Nasal congestion Headache Infection respiratory Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114

AEs

AE	Significance	Dose	Population
Headache	1 patient Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Increased intraocular pressure	1 patient Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Nasal congestion	1 patient Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Nasal mucosal disorder	1 patient Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Colon cancer	2 patients Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Nasal discomfort	2 patients Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Nasal septum ulceration	2 patients Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Sinusitis	2 patients Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Epistaxis	5 patients Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Headache	Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Infection respiratory	Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Nasal congestion	Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Nasopharyngitis	Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114
Sinusitis	Disc. AE	320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114	unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf Page: page 114

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-032489	http://www.3bsc.com/index/pro_info.php?id=53753
AHH Chemical co.,ltd	MT-27153	http://www.ahhchemical.com/product/MT-27153.html
Chem Scene	CS-0120927	http://www.chemscene.com/5534-18-9.html
Chemspace	CSSB00020661129	https://chem-space.com/CSSB00020661129
LGC Standards	LGCFOR0199.01	https://www.lgcstandards.com/US/en/p/LGCFOR0199.01
LGC Standards	MM0199.01-0025	https://www.lgcstandards.com/US/en/p/MM0199.01-0025
Lab Network	LN01274417	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01274417
MedChem Express	HY-136239	https://www.medchemexpress.com/beclomethasone-17-propionate.html
MolPort	MolPort-006-116-979	https://www.molport.com/shop/molecule-link/MolPort-006-116-979
Smolecule	S600542	https://www.smolecule.com/products/s600542
THE BioTek	bt-307443	https://www.thebiotek.com/product/others/bt-307443
eNovation Chemicals	D700538	https://www.enovationchem.com/ProductDetails.asp?ProductID=D700538

PubMed

Title	Date	PubMed
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.	1999 Apr	10100995
Differential potency of beclomethasone esters in-vitro on human T-lymphocyte cytokine production and osteoblast activity.	2000 Apr	10813552
Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts.	2010 Oct 1	20603167
Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway.	2011 Dec	21914487
Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.	2013	23704983
Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes.	2013 May	23512537

Patents

Name

Type

Language

BECLOMETHASONE 17-MONOPROPIONATE

Common Name

English

9-CHLORO-11.BETA.,21-DIHYDROXY-16.BETA.-METHYL-3,20-DIOXOPREGNA-1,4-DIEN-17-YL PROPANOATE

Common Name

English

BECLOMETHASONE 17-PROPIONATE

Common Name

English

BECLOMETHASONE-17-MONOPROPIONATE

Common Name

English

BECLOMETHASONE DIPROPIONATE IMPURITY H [EP IMPURITY]

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 9-CHLORO-11-HYDROXY-16-METHYL-17-(1-OXOPROPOXY)-

Systematic Name

English

9-CHLORO-11B,17,21-TRIHYDROXY-16B-METHYLPREGNA-1,4-DIENE-3,20-DIONE 17-MONOPROPIONATE

Common Name

English

17-BMP

Common Name

English

BECLOMETHASONE DIPROPIONATE RELATED COMPOUND H [USP-RS]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C521